Emerging drugs for renal failure

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 389-435

  Chatterjee, Prabal K ^a   Thiemermann, Christoph ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute renal failure; Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Atrial natriuretic peptide; Chronic renal failure; Cubilin; Dialysis; Diuretics; End stage renal disease; End stage renal failure

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 METHYL 2 (3 PYRIDYL) 1 INDOLEOCTANOIC ACID; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 DICYCLOPROPYLMETHYL 1,3 DIPROPYLXANTHINE; A 206377; ABT 306552; ADENOSINE RECEPTOR BLOCKING AGENT; ALAGEBRIUM; ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; AMBRISENTAN; AMINOPHYLLINE; AMMONOLECT; ANARITIDE; ATRIAL NATRIURETIC FACTOR DERIVATIVE; AURICULIN; BENAZEPRIL; BENZOTHIAZEPINE DERIVATIVE; BUPHENYL; CALCIUM CHANNEL BLOCKING AGENT; CLAZOSENTAN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; EPROSARTAN; FENOLDOPAM; FORSENOL; FR 166124; FUROSEMIDE; GINKGOLIDE B; HMR 4902; IPI 950; L 749329; LOOP DIURETIC AGENT; LU 208075; MANNITOL; NEUREX; ONPI TO; OP 1; OSMOTIC DIURETIC AGENT; PARNAPARIN; PD 159020; PD 159433; PD 164800; PIRMAGREL; PROSTAGLANDIN E1; PYRIDORIN; RENAZORB; RO 24 4736; RUBOXISTAURIN; S 17162; SCH 54470; SLV 320; SM 19712; SOMATOMEDIN; SOMATOMEDIN C; TAK 044; THEOPHYLLINE; THG 213; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE SYNTHASE INHIBITOR; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; VML 252; Z 12571;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LUNG EDEMA; NEPHRITIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; TACHYCARDIA;

CLINICAL TRIALS; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC;

EID: 0346996940     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.389     Document Type: Review

References (374)

1. KAPADIA FN, BHOJANI K, SHAH B: Special issues in the patient with renal failure. Crit. Care Clin. (2003) 19:233-251
2. GOKAL R, HUTCHISON A. Dialysis therapies for end-stage renal disease. Semin. Dial. (2002) 15:220-226.
3. NO AUTHORS LISTED: US Renal Data System: USRDS 2000 Annual Data Report. Atlas of End Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2001).
4. LOCATELLI F, VALDERRABANO F, HOENICH N, BOMMER J, LEUNISSEN K, CAMBI V: Progress in dialysis technology: membrane selection and patient outcome. Nephrol. Dial. Transplant. (2000) 15:1133-1139.
5. RODERICK P, JONES I, RALEIGH VS, MCGEOWN MG, MALLICK NP: Population need for renal replacement therapy in Thames regions: ethnic dimension. Br. Med. J. (1994) 309:1111-1114.
6. NO AUTHORS LISTED: II. Incidence and prevalence of ESRD. Am. J. Kidney Dis. (1999) 34:S40-S50.
7. VALDERRABANO F, BERTHOUX FC, JONES EH, MEHLS O: Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. Nephrol. Dial. Transplant. (1996) 11:2-21.
8. CHUGH K, JHA V: Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int. (1995) 48:S7-S13.
9. SCIEPPATI A, PERICO N, REMUZZI G: Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrol. Dial. Transplant. (2003) 18:858-859.
10. KELLUM JA, LEVIN N, BOUMAN C, LAMEIRE N: Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care (2002) 8:509-514.
11. MEHTA RL, CHERTOW GM: Acute renal failure definitions and classification: time for change? J. Am. Soc. Nephrol. (2003) 14:2178-2187.
12. NISSENSON AR: Acute renal failure: definition and pathogenesis. Kidney Int. (1998) 53:S7-S10.
13. DAGHER PC, HERGET-ROSENTHAL S, RUEHM SG et al: Newly developed techniques to study and diagnose acute renal failure. J. Am. Soc. Nephrol (2003) 14:2188-2198.
14. LLANO F, PASCUAL J: Epidemiology of acute renal failure: a prospective, multicenter, community-based study: Madrid Acute Renal Failure Study Group. Kidney Int. (1996) 50:811-818.
15. THADHANI R, PASCUAL M, BONVENTRE J: Acute renal failure. N. Engl. J. Med. (1996) 334:1448-1460.
16. BRIVET FG, KLEINKNECHT DJ, LORIAT P, LANDAIS PJ: Acute renal. failure in intensive care units: causes, outcome and prognostic factors of hospital mortality: a prospective, multicenter study: French Study Group on Acute Renal Failure. Crit. Care. Med. (1996) 24:192-198.
17. RAHMAN TM, TREACHER D: Management of acute renal failure on the intensive care unit. Clin. Med. (2002) 2:108-113.
18. SMITHIES NN, CAMERON JS: Can we predict outcome in acute renal failure? Nephron (1989) 51:287-300.
19. BELLOMO R, RONCO C: The changing pattern of severe acute renal failure. Nephrology (1991) 2:602-610.
20. GROENEVELD AB, TRAN DD, VAN DER MEULEN J, NAUTA JJ, THIJS LG: Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron (1991) 59:602-610.
21. ZANARDO G, MICHIELON P, PACCAGNELLA A et al: Acute renal failure in the patient undergoing cardiac operation. J. Thorac. Cardiovasc. Surg. (1994) 107:1489-1495.
22. TROPPMAN C, GILLINGHAM KJ, BENEDETTI E et al: Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation (1995) 59:962-968.
23. LAMEIRE N, VANHOLDER R: Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J. Am. Soc. Nephrol. (2001) 12:S20-S32. An expert review of the vascular and tubular factors involved in the pathogenesis of ARF, together with the potential mechanisms of recovery and repair of the injured kidney. A number of experimental and clinical interventions are described and discussed.
24. ALBRIGHT RC: Acute renal failure: a practical update. Mayo Clin. Proc. (2001) 76:67-74.
25. LINDHOLT JS: Radiocontrast induced nephropathy. Eur. J. Vas. Endovasc. Surg. (2003) 25:296-304.
26. NZERUE CM, HEWNA-LOWE K, RILEY LJ JR: Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am. J. Kidney Dis. (2000) 35:783-795.
27. FEEST TG, ROUND A, HAMAD S: Incidence of severe acute renal failure in adults: results of a community based study. Br. Med. J. (1993) 306:481-483.
28. MANNS B, DOIG CJ, LEE H et al.: Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications for renal recovery. Crit. Care Med. (2003) 31:449-455.
29. NO AUTHORS LISTED: National Kidney Foundation - K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. (2002) 39: S1-S266.
30. VANHOLDER R, ARGILES A, BAURMEISTER U et al.: Uremic toxicity: present state of the art. Int. J. Artif. Organs (2001) 24:695-725.
31. WALSER M: Assessing renal function from creatinine measurements in adults with chronic renal failure. Am. J. Kidney Dis. (1998) 32:1-22
32. LEVEY AS, BOSCH J, LEWIS JB et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Int. Med. (1999) 130:461-470.
33. PARMAR MS: Chronic renal disease. Br. Med. J. (2002) 325:85-90. An excellent review of the aetiology, diagnosis and treatment of CRF.
34. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N. Engl. J. Med. (1998) 339:1448-1456.
35. ALEBIOSU CO: An update on 'progression promoters' in renal disease. J. Natl. Med. Assoc. (2003) 95:30-42.
36. SAMUELSSON O, ATTMAN PO: Is smoking a risk factor for progression of chronic renal failure? Kidney Int. (2000) 58:2597.
37. STENGEL B, COUCHOUD C, CENEE S, HEMON D: Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int. (2000) 57:2519-2526.
38. FEEST TG, MISTRY CD, GRIMES DS, MALLICK NP: Incidence of advanced chronic renal failure and need for end-stage replacement therapy. Br. Med. J. (1990) 301:897-900.
39. MAISONNEUVE P, AGODOA L, GELLERT R et al: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am. J. Kidney Dis. (2000) 35:157-165.
40. PRESTON RA, EPSTEIN M: Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J. Hypertens. (1997) 15:1365-1377. An excellent review discussing the pathophysiology of ischaemic renal disease and how it is becoming a major cause of CRF.
41. GOKAL R, FIGUERAS M, OLLE A, ROVIRA J, BADIA X: Outcomes in peritoneal dialysis and haemodialysis: a comparative assessment of survival and quality of life. Nephrol. Dial. Transplant. (1999) 14:24-30.
42. WALKER R: General management of end-stage renal disease. Br. Med. J. (1997) 315:1429-1432.
43. RODERICK PJ, FERRIS G, FEEST TG: The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. Q. J. Med. (1998) 91:581-587.
44. PERAZELLA MA: Acute renal failure in HIV-infected patients: a brief review of common causes. Am. J. Med. Sci. (2000) 319:385-391.
45. LYSAGHT MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol. (2002) 13:S37-S40.
46. LOCATELLI F, VECCHIO LD, POZZONI P: The importance of early detection of chronic kidney disease. Nephrol. Dial. Transplant. (2002) 17:2-7. Outlines the steps that can be taken to reduce the risk or progression of CRF.
47. LEVY EM, VISCOLI CM, HORWITZ RI: The effect of acute renal failure on mortality. JAMA (1996) 275:1489-1494.
48. STAR RA: Treatment of acute renal failure. Kidney Int. (1998) 54:1817-1831. The reasons underlying the relative failure of many recent clinical trials of drugs for the treatment of ARF are discussed in this review.
49. THADHANI R, PASCUAL M, BONVENTRE JV: Medical progress: acute renal failure. N. Engl. J. Med. (1996) 334:1448-1460.
50. NASH K, HAFEEZ A, HOU S: Hospital-acquired renal insufficiency. Am. J. Kidney Dis. (2002) 39:930-936.
51. SING RI N, AHYA SN, LEVIN ML: Acute renal failure. JAMA (2003) 289:747-751
52. CONGER JD: Interventions in clinical acute renal failure: what are the data? Am. J. Kidney Dis. (1995) 26:565-576. Data from many recent clinical trials of drugs for the treatment of ARF are scrutinised in this review.
53. DISHART MK, KELLUM JA: An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs (2000) 59:79-91.
54. LIEBERTHAL W, NIGAM SK: Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable. Am. J. Physiol. Renal Physiol. (2000) 278:F1-F12. An informative discussion of the strengths and weaknesses of experimental models of ARF.
55. DUBOSE TD JR, WARNOCK DG, MEHTA RL et al.: Acute renal failure in the 21st century: recommendations for the management and outcome assessment. Am. J. Kidney Dis. (1997) 29:793-799.
56. HEYMAN SN, LIEBERTHAL W, ROGIERS P, BONVENTRE JV: Animal models of acute tubular necrosis. Curr. Opin. Crit. Care (2002) 8:526-534. Animal models of ischaemic and nephrotoxic ATN are described and discussed.
57. EDELSTEIN CL, LING H, WANSIRIPAISAN A, SCHRIER RW: Emerging therapies for acute renal failure. Am. J. Kidney Dis. (1997) 30:S89-S95.
58. VENKATARAMAN R, KELLUM JA: Novel approaches to the treatment of acute renal failure. Expert Opin. Investig. Drugs (2000) 9:2579-2592. An excellent review outlining the treatments available for ARF up to 2000.
59. KELLY KJ, MILTORIS BA: Acute renal failure in the new millennium: time to consider combination therapy. Semin. Nephrol. (2000) 20:4-19. Convincing arguments as to why multiple therapies are needed for the treatment of ARF in the 21st century.
60. BONVENTRE JV, WEINBERG JM: Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. (2003) 14:2199-2210. An update on the current understanding of the pathophysiology of ischaemic ARF and some recent advances.
61. SIEGEL NJ, SHAH SV: Acute renal failure: directions for the next decade. J. Am. Soc. Nephrol. (2003) 14:2176-2177. A useful commentary on future strategies currently being considered for the therapy of ARF.
62. TAAL MW, BRENNER BM: Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr. Opin. Nephrol. Hypertens. (2001) 10:523-531.
63. TAAL MW, BRENNER BM: Achieving maximal protection in nondiabetic chronic renal disease. Am. J. Kidney Dis. (2001) 38:1365-1371.
64. RUSSO D, PISANI A, BALLETTA MM et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. (1999) 33:851-856.
65. TAAL MW, BRENNER BM: Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr. Opin. Nephrol. Hypertens. (2002) 11:377-381. A good review of the treatment of CRF with ACE inhibitors, angiotensin II receptor antagonists and a combination of both.
66. GILBERT RE, KELLY DJ, ATKINS RC: Novel approaches to the treatment of progressive renal disease. Curr. Opin. Pharmacol. (2001) 1:183-189. An excellent review of the scientific rationale underlying the use of inhibitors of PKC activity and AGE formation for the treatment of CRF.
67. LAMEIRE N, VERBEKE M, VANHOLDER R: Prevention of clinical acute tubular necrosis with drug therapy. Nephrol. Dial. Transplant. (1995) 10:1992-2000.
68. KLAHR S, MORRISSEY J, HRUSKA K, WANG S, CHEN Q: New approaches to delay the progression of chronic renal failure. Kidney Int. Suppl. (2002) 80:23-26
69. KLAHR S, MORRISSEY J: Progression of chronic renal disease. Am. J. Kidney Dis. (2003) 41:S3-S7.
70. NORONHA IL, FUJIHARA CK, ZATZ R: The inflammatory component in progressive renal disease - are interventions possible? Nephrol. Dial. Transplant. (2002) 17:363-368.
71. STENVINKEL P: Inflammation in end-stage renal failure: could it be treated? Nephrol. Dial. Transplant. (2002) 17:33-38
72. STENVINKEL P, ALVESTRNAD A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. (2002) 15:329-337.
73. FUJIHARA CK, MALHEIROS DMAC, ZATZ R, NORONHA IL: Mycophenolate mofetil attenuates renal injury in the rat remnant. Kidney Int. (1998) 54:1510-1519.
74. NOWACK R, BIRCK R, VAN DER WOUDE FJ: Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet (1997) 349:774
75. BRIGGS WA, CHOI MJ, SCHEEL PJ JR: Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. (1998) 31:213-217.
76. BAUD L, FOUQUERAY B, BELLOCQ A: Switching off renal inflammation by anti-inflammatory mediators: the facts, the promise and the hope. Kidney Int. (1998) 53:1118-1126.
77. ITO Y, ATEN J, BENDE RJ et al.: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. (1998) 53:853-861.
78. KLAHR S: Progression of chronic renal disease. Heart Dis. (2001) 3:205-209.
79. CHIARELLI F, TROTTA D, VERROTTI A, MOHN A: Kidney involvement and disease in patients with diabetes. Panminerva Med. (2003) 45:23-41.
80. YU HT: Progression of chronic renal failure. Arch. Intern. Med. (2003) 163:1417-1429.
81. CHENG J, GRANDE JP: Transforming growth factor-beta signal transduction and progressive renal disease. Exp. Biol. Med. (2002) 227:943-956.
82. BORDER WA, NOBLE NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension (1998) 31:181-188.
83. GAEDEKE J, NOBLE NA, BORDER WA: Angiotensin II and progressive renal insufficiency. Curr. Hypertens. Rep. (2002) 4:403-407.
84. PARK J-K, MÜLLER DN, MERVAALA EMA et al.: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. (2000) 58:1420-1430.
85. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. (2002) 136:604-615.
86. WEDER AB: Renal protective effects of angiotensin converting enzyme inhibitors. Am. J. Hypertens. (1990) 3:273S-277S.
87. MACKENZIE HS, ZIAI F, OMER SA, NADIM MK, TAAL MW: Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future. J. Am. Soc. Nephrol. (1999) 10:S283-S286.
88. SCHNACKENBERG CG: Oxygen radicals in cardiovascular-renal disease. Curr. Opin. Pharmacol. (2002) 2:121-125.
89. MASSY ZA, NGUYEN-KHOA T: Oxidative stress and chronic renal failure: markers and management. J. Nephrol. (2002) 15:336-341.
90. WARDLE EN: Antioxidants in the prevention of renal disease. Ren. Fail. (1999) 21:581-591.
91. TARNG DC, WEI YH, HUANG TP, KUO BI, YANG WC: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. (1999) 55:2477-2486.
92. CRISTOL JP, BOSC JY, BADIOU S et al.: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol. Dial. Transplant. (1997) 12:2312-2317.
93. HERRERA J, NAVA M, ROMERO F, RODRIGUEZ-ITURBE B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am. J. Kidney Dis. (2001) 37:750-757.
94. FILLER G: Acute renal failure in children: aetiology and management. Paediatr. Drugs (2001) 3:783-792.
95. FLYNN JT: Causes, management approaches, and outcomes of acute renal failure in children. Curr. Opin. Pediatr. (1998) 10:184-189.
96. TRACHTMAN H: Diagnosis and treatment of chronic renal failure in children. Am. J. Manag. Care (1997) 3:785-788.
97. HARMON WE: Treatment of children with chronic renal failure. Kidney Int. (1995) 47:951-961.
98. VESELY DL: Natriuretic peptides and acute renal failure. Am. J. Physiol. (2003) 285:F167-F177.
99. SHAW SG, WEIDMANN P, HODLER J, ZIMMERMANN A, PATERNOSTRO A: Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J. Clin. Invest. (1987) 80:1232-1237.
100. CONGER JD, FALK SA, HAMMOND WS: Atrial natriuretic peptide and dopamine in established acute renal failure in the rat. Kidney Int. (1991) 35:1126-1132.
101. RAHMAN SN, KIM GE, MATHEW AS et al.: Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. (1994) 45:1731-1738.
102. ALLGREN RL, MARBURY TC, RAHMAN SN et al.: Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N. Engl. J. Med. (1997) 336:828-834.
103. LEWIS J, SALEM MM, CHERTOW GM et al.: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am. J. Kidney Dis. (2000) 36:767-774.
104. SAXENHOFER H, RASELLI A, WEIDMANN P et al.: Urodilantin, a natriuretic factor from kidneys can modify renal and cardiovascular system in men. Am. J. Physiol. (1990) 259:F832-F838.
105. MEYER M, RICHTER R, FORSSMANN WG: Urodilatin, a natriuretic peptide with clinical implications. Eur. J. Med. Res. (1998) 3:103-110.
106. HUMNEL M, KUHN M, BUB A et al.: Urodilantin: a new peptide with beneficial effects in post-operative therapy of cardiac transplant recipients. Clin. Invest. (1992) 70:647-682.
107. WIEBE K, MEYER M, WAHLERS T et al.: Acute renal failure following cardiac surgery is reversed by administration of urodilantin (INN: Ularitide). Eur. J. Med. Res. (1996) 1:259-265.
108. CEDIDI C, KUSE ER et al.: Urodilantin: a new approach for treatment of therapy-resistant acute renal failure after liver transplantation. Eur. J. Clin. Invest. (1994) 24:632-639.
109. MEYER M, PFARR E, SCHIRMER G et al.: Therapeutic use of natriuretic peptide ularitide in acute renal failure. Ren. Fail. (1999) 21:85-100.
110. MILLER ED: Renal effects of dopamine. Anesthesiology (1984) 61:487-488.
111. REDDY VG: Prevention of postoperative acute renal failure. J. Postgrad. Med. (2002) 48:64-70.
112. DENTON MD, CHERTOW GM, BRADY HR: 'Renal-dose' dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. (1996) 50:4-14.
113. BURTON CJ, TOMSON CR: Can the use of low dose dopamine for treatment of acute renal failure be justified? Postgrad. Med. J. (1999) 75:269-274.
114. KELLUM JA, DECKER JM: Use of dopamine in acute renal failure: a meta analysis. Crit. Care Med. (2001) 29:1526-1531.
115. OLSEN NV, HAMSEN JM, LADEFOGED SD et al.: Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin. Sci. (1990) 78:503-507.
116. ALLISON NL, DUBB JW, ZIEMNIAK JA, ALEXANDER F, STOTE RM: The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin. Pharmacol. Ther. (1987) 41:282-288.
117. ELLIOTT WJ, WEBER RR, NELSON KS et al.: Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation (1990) 81:970-977.
118. NICHOLS AJ, KOSTER PF, BROOKS DP, RUFFOLO RR JR: Effect of fenoldopam on the acute and subacute nephrotoxic renal failure produced by amphoteracin B in the dog. J. Pharmacol. Exp. Ther. (1992) 260:269-274.
119. HEDRICH D, STOTE RM: Fenoldopam reverses cyclosporine-A induced renal vasoconstriction in kidney transplant recipients. Am. J. Kidney Dis. (1992) 19:567-572.
120. SHUSTER HP, SUTER PM, HEMMER M, CLEMENS R, BODMAN KF, RAMNOD J: Fenoldopam improves renal dysfunction secondary to ventilation with PEEP. Intensive Care Med. (1991) 28:348-355.
121. MATHUR VS, SWAN SK, LAMBRECHT LJ et al.: The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit. Care Med. (1999) 27:1832-1837.
122. MUNGER M, BENOTTI J, GREEN J, JARVIS RC: Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. Am. J. Cardiol. (1990) 65:206-210.
123. HANDENGUE A, MOREAU R, BACQ Y, GAUDIN C, BRAILLON A, LEBREC D: Selective dopamine receptor-1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal homodynamic study. Hepatology (1991) 13:111-116.
124. 1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev. Cardiovasc. Med. (2003) 4:S35-S40.
125. YOUNG EW, HUMES HD: Calcium and acute renal failure. Miner. Electrolyte Metab. (1991) 17:106-111.
126. PEARCE CJ, WALLIN JD: Calcium antagonists and the kidney. New Horiz. (1996) 4:123-128.
127. EPSTEIN M: Calcium antagonists and the kidney. Future therapeutic perspectives. Am. J. Kidney Dis. (1993) 21:16-25.
128. EPSTEIN M, DE MICHELLI AG, FORSTER H: Natriuretic effects of calcium antagonists in humans: a review of experimental evidence and clinical data. Cardiovasc. Drug Rev. (1991) 9:399-413.
129. LEONETTI G, RAPPELLI A: Are there differences in the renal effects of calcium antagonists? J. Hypertens. (1993) 11:S45-S48.
130. KORSTANJE C: Barnidipine, a long-acting slow onset calcium antagonist. Int. J. Clin. Pract. Suppl. (2000) 114:2-5.
131. LEE SM, HILLMAN BJ, CLARK RL, MICHAEL UF: The effects of diltiazem and captopril on glycerol-induced acute renal failure in the rat: function, pathologic and microangiographic studies. Invest. Radiol. (1985) 20:961-970.
132. WATSON AJ, GIMINEZ LF, KLASSEN DK, STOUT RL, WHETTON A: Calcium-channel blockade in experimental aminoglycoside nephrotoxicity. J. Clin. Pharmacol. (1987) 27:625-627.
133. NEUMAYER HH, JUNGE W, KUFNER A, WENNING A: Prevention of radiocontrast-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective, randomised clinical trial. Nephrol. Dial. Transplant. (1989) 4:1030-1036.
134. RUSSO D, TESTA A, DELLA VL, SANSONE G: Randomized prospective study on renal effects of two different contrast media in humans: protective role of calcium channel blocker. Nephron (1990) 55:254-257.
135. BERG KJ, HOLDASS H, ENDRESEN L et al.: Effects of isradipine on renal function in cyclosporine-treated renal transplanted patients. Nephrol. Dial. Transplant. (1991) 6:725-730.
136. NEUMAYER HH, KUNZENDORF U, SCHREIBER M: Protective effects of diltiazem and prostacyclin analogue iloprost in human renal transplantation. Ren. Fail. (1992) 14:289-296.
137. CACOUB P, DERAY G, BAUMELOU A et al.: No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin. Nephrol. (1988) 29:215-216.
138. VAN RIEMSDIJK IC, MULDER PG, DE FIJTER JW et al.: Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomised, placebo-controlled, multi-center study. Transplantation (2000) 70:122-126.
139. LOUTZENHISER R, EPSTEIN M, HORTON C, SONKE P: Reversal of renal and smooth muscle actions of thromboxane mimetic U-44069 by diltiazem. Am. J. Physiol. (1986) 251:F581-F587.
140. YEE GC, MCGUIRE TR: Pharmacokinetic drug interactions with cyclosporine (Part 1). Clin. Pharmacokinet. (1990) 19:319-332.
141. KING AJ, BRENNER BM, ANDERSON S: Endothelin: a potent renal and systemic vasoconstrictor peptide. Am. J. Physiol. (1989) 256:F1051-F1058.
142. NORD EP: Role of endothelin in acute renal failure. Blood Purif. (1997) 15:273-285.
143. SHIBOUTA Y, SUZUKI N, SHINO A et al.: Pathophysiolgical role of endothelin in acute renal failure. Life Sci. (1990) 46:1611-1618.
144. TOMITA K, UJJIE K, NAKANISHI T et al.: Plasma endothelin levels in patients with acute renal failure. N. Engl. J. Med. (1989) 321:1127.
145. FORBES JM, JANDELEIT-DAHM K, ALLEN TJ, HEWITSON TD, BECKER GJ, JONES CL: Endothelin and endothelin A/B receptors are increased after ischaemic acute renal failure. Exp. Nephrol. (2001) 9:309-316.
146. ORLEANS-JUSTE PD, LABONTE J, BKALIY G, CHOUFANI S, PLANTE M, HONORE JC: Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. (2002) 95:221-238
147. CHAN L, CHITTINANDANA A, SHAPIRO JI, SHANLEY PF, SCHRIER RW: Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am. J. Physiol. (1994) 266:F135-F138.
148. GELLAI M, JUGUS M, FLETCHER T et al.: Nonpeptide endothelin receptor antagonists. V. Prevention and reversal of acute renal failure in the rat by SB209670. J. Pharmacol. Exp. Ther. (1995) 275:200-206.
149. HUANG C, HUANG C, HESTIN D et al.: The effect of endothelin antagonists on renal ischaemia-reperfusion injury and the development of acute renal failure in the rat. Nephrol. Dial. Transplant. (2002) 17:1578-1585.
150. BROOKS DP, CONTINO LC: Prevention of cyclosporin A-induced renal vasoconstriction by the endothelin receptor antagonist SB209670. Eur. J. Pharmacol. (1995) 294:571-576.
151. POLLOCK DM, POLAKOWSKI JS, WEGNER CD, OPGENORTH TJ: Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Ren. Fail. (1997) 19:753-761.
152. WANG A, HOLCSCLAW T, BASHORE TA et al.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. (2000) 57:1675-1680.
153. RUETTEN H, THIEMERMANN C, VANE JR: Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetised rat. Br. J. Pharmacol. (1996) 118:198-204.
154. CRISTOL JP, WARNER TD, THIEMERMANN C, VANE JR: Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetised rat. Br. J. Pharmacol. (1993) 108:776-779.
155. FORBES JM, HEWITSON TD, BECKER GJ, JONES CL: Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. (2001) 59:1333-1341.
156. ROHMEISS P, BIRCK R, BRAUN C, KIRCHENGAST M, VAN DERWOUDE F: Targets for endothelin in the diseased kidney: clues for therapeutic intervention. Exp. Nephrol. (1999) 7:1-10.
157. MCCOY DE, BHATTACHARYA S, OLSON BA, LEVIER DG, AREND LJ, SPIELMAN WS: The renal adenosine system: structure, function, and regulation. Semin. Nephrol. (1993) 13:31-40.
158. WEIHPRECHT H, LORENZ JN, BRIGGS JP, SCHNERMANN J: Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am. J. Physiol. (1994) 266:F227-F239.
159. AREND LJ, BAKRIS GL, BURNETT JC JR et al.: Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J. Lab. Clin. Med. (1987) 110:406-411.
160. ABIZAID AS, CLARK CE, MINTZ GS et al.: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am. J. Cardiol. (1999) 83:260-263.
161. KOLONKO A, WIECEK A, KOKOT F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J. Nephrol. (1998) 11:151-156.
162. ERLEY CM, DUDA SH, REHFUSS D et al.: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol. Dial. Transplant. (1999) 14:1146-1149.
163. AGMON Y, DINOUR D, BREZIS M: Disparate effects of adenosine A1- and A2-receptor agonists on intrarenal blood flow. Am. J. Physiol. (1993) 265:F802-F806.
164. 2A adenosine receptor: a novel therapeutic target in renal disease. Am. J. Physiol. Renal Physiol. (2002) 282:F10-F18.
165. SHILLIDAY I, ALLISON ME: Diuretics in acute renal failure. Renal Fail. (1994) 16:3-17.
166. STEIN JH: Acute renal failure: lessons from pathophysiology. West. J. Med. (1992) 156:176-182.
167. MAJUMDAR S, KJELLSTRAND CM: Why do we use diuretics in acute renal failure? Semin. Dial. (1996) 9:454-459.
168. KELLUM JA: Use of diuretics in the acute care setting. Kidney Int (1998) 53:S67-S70.
169. ROMANO G, FAVARET G, FEDERICO E, BARTOLI E: The site of action of furosemide. Pharmacol. Res. (1998) 37:409-419.
170. KLEINKNECHT D, GANEVAL D, GONZALES-DUQUE LA, FERMANIAN J: Furosemide in acute oliguric renal failure. A controlled trial. Nephron (1976) 17:51-58.
171. BROWN CB, OGG CS, CAMERON JS: High dose furosemide in acute renal failure. A controlled trial. Clin. Nephrol. (1981) 15:90-96.
172. SHILLIDAY IR, QUINN KJ, ALLISON ME: Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomised study. Nephrol. Dial Transplant. (1997) 12:2592-2596.
173. SOLOMON R, WERNER C, MANN D, D'ELLA J, SILVA P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N. Engl. J. Med. (1994) 331:1416-1420.
174. SANDERS PW, BOOKER BB, BISHOP JB, CHEUNG HC: Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J. Clin. Invest. (1990) 85:570-578.
175. WIGAND ME, HEIDLAND A: Ototoxic side-effects of high doses furosemide in patients with uremia. Postgrad. Med. J. (1971) 47:54-56.
176. BETTER OS, RUBINSTEIN I, WINAVER JM, KNOCHEL JP: Mannitol therapy revisited. (1940-1997). Kidney Int. (1997) 52:886-894.
177. BONVENTRE JV, WEINBERG JM: Kidney preservation ex vivo for transplantation. Ann. Rev. Med. (1992) 43:523-553.
178. BEALL AC, HOLMAN MR, MORRIS GC et al.: Mannitol -induced osmotic diuresis during vascular surgery. Arch. Surg. (1963) 86:34-42.
179. POWERS SR, BOBA A, HOSTNIK W et al.: Prevention of post-operative acute renal failure with mannitol in 100 cases. Surgery (1964) 35:15-23.
180. IP-YAM PC, MURPHY S, BAINES M et al.: Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth. Analg. (1994) 78:842-847.
181. GUBERN JM, SANCHO JJ, SIMO J et al.: A randomised trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery (1988) 103:39-44.
182. BREZIS M, AGMON Y, EPSTEIN FH: Determinants of intrarenal oxygenation. I. Effects of diuretics. Am. J. Physiol. (1994) 267: F1059-F1062.
183. DORMAN HR, SONDHEIMER JH, CHADNAPAPHORNCHAI P: Mannitol-induced acute renal failure. Medicine (1990) 69:153-159.
184. HAMMERMANN MR, SAFIRSTEIN R, HARRIS RC et al.: Acute renal failure. III. The role of growth factors in the process of renal regeneration and repair. Am. J. Physiol. (2000) 279:F3-F11.
185. O'SHEA MH, MILLER SB, HAMMERMANN MR: Effects of IGF-I on renal function in patients with chronic renal failure. Am. J. Physiol. (1992) 262:F540-F545.
186. FRANKLIN SC, MOULTON M, SICARD GA, HAMMERMANN MR, MILLER SB: Insulin-like growth factor I preserves renal function post-operatively. Am. J. Physiol. (1997) 272:F257-F259.
187. HIRSCHBERG R, KOPPLE J, LIPSETT P et al.: Multicenter clinical trial of recombinant human insulin-like growth Factor I in patients with acute renal failure. Kidney Int. (1999) 55:2423-2432.
188. LIU KD: Molecular mechanisms of recovery from acute renal failure. Crit. Care Med. (2003) 31:S572-S581.
189. TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increased mortality associated with growth hormone treatment in critically ill patients. N. Engl. J. Med. (1999) 341:785-792.
190. CRONIN RE, BROWN DM, SIMONSEN R: Protection by thyroxine in nephrotoxic acute renal failure. Am. J. Physiol. (1986) 251:F408-F416.
191. SIEGEL NJ, GAUDIO KM, KATZ LA et al.: Beneficial effect of thyroxin on recovery from toxic acute renal failure. Kidney Int. (1984) 25:906-911.
192. STRAUB E: Effects of L-thyroxine in acute renal failure. Res. Exp. Med. (1976) 168:81-87.
193. ACKER CG, SINGH AR, FLICK RP, BERNARDINI J, GREENBERG A, JOHNSON JP: A trial of thyroxine in acute renal failure. Kidney Int. (2000) 57:293-298.
194. ACKER CG, FLICK R, SHAPIRO R et al.: Thyroid hormone in the treatment of post-transplant acute tubular necrosis (ATN). Am. J. Transplant. (2002) 2:57-61.
195. LOPEZ-NOVOA JM: Potential role of platelet activating factor in acute renal failure. Kidney Int. (1999) 55:1672-1682.
196. KELLY KJ, TOLKOFF-RUBIN NE, RUBIN RH et al: An oral platelet-activating antagonist, Ro-24-4736, protects the rat kidney from ischemic injury. Am. J. Physiol. (1996) 271:F1O61-F1067.
197. GRINYO JM: BN 52021: A platelet-activating-factor antagonist for preventing post-transplant renal failure: a double-blind, randomised study: The BN 52021 Study group in Renal Transplantation. Ann. Intern. Med. (1994) 121:345-347.
198. GRINYO JM, TORRAS J, VALLES J: The role of platelet-activating-factor antagonists in posttransplant acute tubular necrosis. Ren. Fail. (1996) 18:445-451.
199. BAGNIS C, DERAY G, DUBOIS M et al.: Prevention of cyclosporine nephrotoxicity with a platelet-activating-factor antagonist. Nephrol. Dial Transplant. (1996) 11:507-513.
200. KOCH JA, PLUM J, GRABENSEE B, MODDER U: Prostaglandin E1: A new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol. Dial. Transplant. (2000) 15:43-49.
201. STORK JE, RAHMAN MA, DUNN MJ: Eicosanoids in experimental and human renal disease. Am. J. Med. (1986) 80:34-45.
202. SMITH SR, CREECH EA, SCHAFFER AV et al.: Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney Int. (1992) 41:199-205.
203. SMITH SR, KUGACHI VB, RAKHIT A et al.: Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation (1993) 56:1422-1426.
204. ELZINGA L, KELLY V, HOUGHTON D: Fish oil modifies experimental cyclosporine nephrotoxicity and decreases renal prostaglandins. Transplantation (1987) 43:271-273.
205. VAN DER HEIDE JH, BILO HJG, DONKER JM et al.: Effect of dietary fish oil on renal function and rejection in cyclosporine treated recipients of renal transplants. N. Engl. J. Med. (1993) 329:769-773.
206. DIMARI J, MEGYESI J, UDVARHELYI N, PRICE P, DAVIS R, SAFIRSTEIN R: N-acetyl cysteine ameliorates ischemic renal failure. Am. J. Physiol. (1997) 272:F292-298.
207. ASIF A, PRESTON RA, ROTH D: Radiocontrast-induced nephropathy. Am. J. Ther. (2003) 10:137-147.
208. DEAN LS: Protection from contrast-induced nephropathy: is the answer in? Catheter Cardiovasc. Interv. (2003) 58:342-343.
209. BAKER CS, WRAGG A, KUMAR S, DE PALMA R, BAKER LR, KNIGHT CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J. Am. Coll. Cardiol. (2003) 41:2114-2118.
210. TEPEL M, VAN DER GIET M, SCHWARZFELD C, LAUFER U, LIERMANN D, ZIDEK W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine, N. Engl. J. Med. (2000) 343:180-184.
211. KAY J, CHOW WH, CHAN TM et al.: Acetylcysteine for prevention of acute deterioration of renal function following selective coronary angiography and intervention: a randomised controlled trial. JAMA (2003) 289:553-558.
212. SMYU KG, CHENG JJ, KUAN P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol. (2002) 40:1383-1388.
213. DURHAM JD, CAPUTO C, DOKKO J et al.: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. (2002) 62:2202-2207.
214. BOCCALANDRO F, AMHAD M, SMALLING PW, SDRINGOLA S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc. Interv. (2003) 58:336-341.
215. ALLAQABAND S, TUMULURI R, MALIK AM et al.: Prospective randomised study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc. Interv. (2002) 57:279-283.
216. TEPEL M, VAN DER GIET M, STATZ M, JANKOWSKI J, ZIDEK W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomised, controlled trial. Circulation (2003) 107:992-995.
217. ALATAS O, SAHIN A, COLAK O et al.: Beneficial effects of allopurinol on glutathione levels and glutathione peroxidase activity in rat ischaemic acute renal failure, J. Int. Med. Res. (1996) 24:33-39.
218. TOLEDO-PEREYRA LH, SIMMONS RL, OLSON LC et al.: Clinical effect of allopurinol on preserved kidneys. Am. Surg. (1977) 185:128-131.
219. WEINBERG JM: The cell biology of ischemic renal injury. Kidney Int. (1991) 31:476-500.
220. SCHNEEBERGER H, ILLBER WD, AVENDROTH D et al.: First clinical experiences with superoxide dismutase in kidney transplantation - results of a double-blind randomised study. Transplant Proc. (1989) 21:1245-1246.
221. BAYATI A, HELLBERG O, ODLIND B, WOLGAST M: Prevention of ischaemic acute renal failure with superoxide dismutase and sucrose. Acta Physiol. Scand. (1987) 130:367-372.
222. KONYA L, SZENASI G, BENCSATH P, FEHER J: Study of the effect of superoxide dismutase on acute renal failure in dogs. Acta Med. Hung. (1991) 48:79-85.
223. WOLF G: Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol. Dial. Transplant. (1999) 14:42-44.
224. WIECEK A, CHUDEK J, KOKOT F: Role of angiotensin II in the progression of diabetic nephropathy - therapeutic implications. Nephrol. Dial. Transplant. (2003) 18:v16-v20.
225. 1 receptor antagonists in patients with chronic renal disease. J. Am. Soc. Nephrol. (2002) 13:1100-1108.
226. LEWIS EJ, HUNSICKER LG, BAIN RP et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. (1993) 329:1456-1462.
227. MASCHIO G, ALBERTI D, JANIN G et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. (1996) 334:939-945.
228. BAKRIS GL, WEIR M: ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence? J. Clin. Hypertens. (2002) 4:420-423.
229. MASCHIO G, MARCANTONI C, BERNICH P: Lessons from large interventional trials on antihypertensive therapy in chronic renal disease. Nephrol. Dial. Transplant. (2002) 17:47-49.
230. WENZEL UO: Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib. Nephrol. (2001) 135:200-211.
231. NO AUTHORS LISTED: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br. Med. J. (1998) 317:713-720.
232. ESTACIO R, JEFFERS B, GIFFORD N et al.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care (2000) 23:B54-B64.
233. NO AUTHORS LISTED: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet (2000) 355:253-259.
234. NO AUTHORS LISTED: Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Ann. Intern. Med. (2001) 134:370-379.
235. KSHIRSAGAR AV, JOY MS, HOGAN SL, FALK RJ, COLINDRES RE: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systemic overview of randomised placebo-controlled trials. Am. J. Kidney Dis. (2000) 35:695-707.
236. WRIGHT JT, BAKRIS G, GREENE T et al.: Effect of blood pressure lowering and anti hypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA (2002) 288:2421-2431.
237. NO AUTHORS LISTED: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet (1997) 349:1857-1863.
238. RUGGENENTI P, PERNA A, GHERARDI G et al.: Chronic proteinuric nephropathies: outcome and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. (2000) 35:1155-1165.
239. JAFAR TH, SCMID CH, LANDA M et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann. Intern. Med. (2001) 135:73-87.
240. TARIF N, BAKRIS GL: Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int. (1997) 63:S67-S70.
241. KIM S, IWAO H: Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and cellular phenotype. J. Hypertens. (1997) 15:S3-S7.
242. ZATZ R, FUJIHARA CK: Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide. J. Hypertens. 20:S37-S44.
243. PRICE DA, HOLLENBERG NK: Angiotensin receptor blockers in diabetic nephropathy. Curr. Diab. Rep. (2001) 1:267-274.
244. SONKODI S, MOGYOROSI A: Treatment of diabetic nephropathy with angiotensin II blockers. Nephrol. Dial. Transplant. (2003) 18:v21-v23.
245. BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
246. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
247. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. (2001) 345:870-878.
248. VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation (2002) 106:672-678.
249. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. (2000) 57:1803-1817.
250. FERRARIO CM, CHAPPELL MC, DEAN RH, IYER SN: Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J. Am. Soc. Nephrol. (1998) 9:1716-1722.
251. CAO Z, BONNET F, DAVIS B et al.: Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin. Sci. (2001) 100:591-599.
252. KOHZUKI M, YASUJIMA M, KANAZAWA M et al.: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J. Hypertens. (1995) 13:97-103.
253. NAKAO N, YOSHIMURA A, MORITA H et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2003) 361:117-124.
254. RUSSO D, PISANI A, BALLETTA MM et al.: Additive antiproteinuric effect of converting enzyme and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. (1999) 33:851-856.
255. RUILOPE LM, ALDIGIER JC, PONTICELLI C et al.: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J. Hypertens. (2000) 18:89-95.
256. FERRARI P, MARTI H, PFISTER M et al.: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II blockade. J. Hypertens. (2002) 20:125-130.
257. DELLES C, JACOBI J, JOHN S et al.: Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int. (2002) 20:125-130.
258. MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. J. Med. (2000) 321:1440-1444.
259. ROSSING K, CHRISTENSEN PK, JENSEN BR et al.: Dual blockage of the renin-angiotensin system in diabetic nephropathy. Diabetes Care (2002) 25:95-100.
260. HEBERT LA, FALKENHAIN ME, NAHMAN NS et al.: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am. J. Nephrol. (1999) 19:1-6.
261. KINCAID-SMITH P, FAIRLEY K, PACKHAM D: Randomised controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol. Dial. Transplant. (2002) 17:597-601.
262. AGARWAL R: Add-on angiotensin receptor blockade with maximised ACE inhibition. Kidney Int. (2001) 59:2282-2289.
263. AGARWAL R, SIVA S, DUNN SR et al.: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am. J. Kidney Dis. (2002) 39:486-492.
264. ODA H, KEANE WF: Recent advances in statins and the kidney. Kidney Int. (1999) 56:S2-S5.
265. GUIJARRO C, KEANE WF: Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner. Electrolyte Metab. (1996) 22:147-152.
266. KASISKE BL, O'DONNELL MP, GARVIS WL, KEANE WF: Pharmacological treatment of hyperlipidaemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ. Res. (1988) 62:367-374.
267. O'DONNELL MP, KASISKE BL, KIM Y, SCMITZ PG, KEANE WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am. J. Kidney Dis. (1993) 22:83-89.
268. HARRIS KP, PURKERSON ML, YATES J, KLAHR S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephritic syndrome. Am. J. Kidney Dis. (1990) 15:16-23.
269. WHEELER DC: Are there potential non-lipid-lowering uses of statins? Drugs (1998) 56:517-522.
270. BELLOSTA S, BERNINI F, FERRI N et al.: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis (1998) 137:S101-S109.
271. PARK J-K, MÜLLER DN, MERVAALA EMA et al.: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure and cholesterol-lowering effects. Kidney Int. (2000) 58:1420-1430.
272. TONELLI M, MOYE L, SACKS FM et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med (2003) 138:98-104.
273. MARTINEZ-CASTELAO A, GRINYO JM, GIL-VERNET S et al.: Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplant. Proc. (2002) 34:398-400.
274. FRIED LF, ORCHARD TJ, KASISKE BL: The effect of lipid reduction on the progression of renal disease. A meta-analysis. Kidney Int. (2001) 59:260-269.
275. KOYA D, JIROUSEK MR, YOU-WEI L, ISHII H, KUKOKI K, KING GL: Characterisation of protein kinase Cβ isoform activation on gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. (1997) 100:115-126.
276. FENG X, ZHANG J, BARAK LS, MEYER T, CARON MG, HANNUN YA: Visualisation of dynamic trafficking of a protein kinase C βII/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitisation. J. Biol. Chem. (1998) 273:10755-10762.
277. GOEKJIAN PG, JIROUSEK MR: Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem. (1999) 6:877-903.
278. KOYA D, HANEDA M, NAKAGAWA H et al.: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. (2000) 14:439-447.
279. ISHII H, JIROUSEK MR, KOYA D et al.: Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor. Science (1996) 272:728-731.
280. KELLY DJ, ZHANG Y, HEPPER C et al.: Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 52:512-518.
281. RAJ DSC, CHOUDHURY D, WELBOURNE TC, LEVI M: Advanced glycation end products: a nephrologist's perspective. Am. J. Kidney Dis. (2000) 35:365-380.
282. ARONSON D: Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med. Hypotheses (2002) 59:297-301.
283. BENDAYAN M: Immunological detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int. (1998) 54:438-447.
284. SOULIS T, THALLAS V, YOUSSEF S et al.: Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia (1997) 40:619-628.
285. FORBES JM, COOPER ME, OLDFIELD MD, THOMAS MC: Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. (2003) 14:S254-S258.
286. HEIDLAND A, SEBEKOVA K, SCHINZEL R: Advanced glycation end products and the progressive course of renal disease. Am. J. Kidney Dis. (2001) 38:S100-S106.
287. HE CJ, ZHENG F, STITT A, STRIKER L, HATTORI M, VLASSARA H: Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int. (2000) 58:1931-1940.
288. VLASSARA H, COHEN JJ, MADIAS NE et al.: Protein glycation in the kidney - role in diabetes and aging. Kidney Int. (1996) 49:1795-1804.
289. HUANG JS, GUH JY, HUNG WC et al.: Role of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem. J. (1999) 342:231-238.
290. HUTTUNEN HJ, FAGES C, RAUVALA H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signalling pathways. J. Biol. Chem. (1999) 274:19919-19924.
291. LANDER HM, TAURAS JM, OGISTE JS, HORI O, MOSS RA, SCHMIDT AM: Activation of the receptor for advanced glycation end products triggers a p21 (Ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. (1997) 272:17810-17814.
292. SCHMIDT AM, STERN DM: RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. (2000) 11:368-375.
293. EDELSTEIN D, BROWNLEE M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes (1992) 41:26-29.
294. SOLULIS T, COOPER ME, VRANES D, BUCALA R, JERUMS G: The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of duration of treatment. Kidney Int. (1996) 50:627-634.
295. SOULIS-LIPAROTA T, COOPER M, PAPAZOGLOU D, CLARKE B, JERUMS G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes (1991) 40:1328-1334.
296. FREEDMAN BI, WUERTH JP, CARTWRIGHT K et al.: Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials (1999) 20:493-510.
297. VASAN S, ZHANG X, KAPURNIOTU A et al.: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 382:275-278.
298. WOLFFENBUTTEL BH, BOULANGER CM, CRIJNS FR et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. USA (1998) 95:4630-4634.
299. FORBES JM, THALLAS V, THOMAS MC et al.: The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. (2003) 17(12):1762-1764.
300. VOZIYAN PA, METZ TO, BAYNES JW, HUDSON BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. (2002) 277:3397-3403.
301. ALDERSON NL, CHACHICH ME, YOUSSEF NN et al.: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. (2003) 63:2123-2133.
302. DEGENHARDT TP, ALDERSON NL, ARRINGTON DD et al.: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. (2002) 61:939-950.
303. DEGENHARDT TP, KHALIFAH RG, KLAICH GM, SCHOTZINGER RJ: Pharmacokinetics, tolerability and biologic activity of oral Pyridorin, a novel AGE inhibitor, in patients with Type I diabetes and diabetic nephropathy. 35th Annual Meeting of the American Society of Nephrology (2002) (Abstract SU-P0893). Report from the first clinical trial investigating the effects of pyridoxamine dihydrochloride (Pyridorin), an orally active AGE inhibitor, on diabetic nephropathy.
304. FIGAROLA JL, SCOTT S, LOERA S et al.: LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia (2003) 46:1140-1152.
305. BURNETT JC JR: Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertens. (1999) 17:S37-S43.
306. BURNETT JC: Vasopeptidase inhibition. Curr. Opin. Nephrol. Hypertens. (2000) 9:465-468.
307. SUSIC D: Renal protective potential of antihypertensive drugs. Expert Opin. Investig. Drugs (2000) 9:2593-2600.
308. KUBOTA E, DEAN RG, HUBNER RA, BALDING LC, JOHNSON CI, BURRELL LM: Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. Curr. Hypertens. Rep. (2001) 3:S31-S33.
309. KUBOTA E, DEAN RG, BALDING LC, BURRELL LM: Inhibition of peptidases in the control of blood pressure. Essays Biochem. (2002) 38:129-139.
310. COHEN DS, MATHIS JE, DOTSON RA, GRAYBILL SR, WOSU NJ: Protective effects of CGS30440, a combined angiotensin-converting enzyme inhibitor and neutral peptidase inhibitor, in a model of chronic renal failure. J. Cardiovasc. Pharmacol. (1998) 32:778-785.
311. TAAL M, NENOV VD, WONG W et al.: Vasopeptidase inhibition affords greater renoprorection than angiorensin-converting enzyme inhibition alone, J. Am. Soc. Nephrol. (2001) 12:2051-2059.
312. DAVIS BJ, JOHNSTON CI, BURRELL LM et al.: Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia (2003) 46(7):961-971.
313. QUASCHNING T, GALLE J, WANNER C: Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. Kidney Int. (2003) 84:54-57.
314. CAMPBELL DJ: Vasopeptidase inhibition: a double-edged sword? Hypertention (2003) 41:383-389.
315. TOMLINSON DR, STEVENS EJ, DIEMAL LT: Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci. (1994) 15:293-297.
316. PASSARIELLO N, SEPE J, MARAAZZO G et al.: Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care (1993) 16:789-795.
317. SUKI WN: Use of diuretics in chronic renal failure. Kidney Int. (1997) 59:S33-S35.
318. WILCOX CS: New insights into diuretic use in patients with chronic renal disease. J. Am. Soc. Nephrol. (2002) 13:798-805.
319. ANDREUCCI M, RUSSO D, FUIANO G, MINUTOLO R, ANDREUCCI VE: Diuretics in renal failure. Miner. Electrolyte Metab. (1999) 25:32-38.
320. PERSSON PB: Nitric oxide in the kidney. Am. J. Physiol. Integr. Comp. Physiol. (2002) 283 R1005-R1007.
321. SCHMIDT RJ, BAYLIS C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. (2000) 58:1261-1266.
322. MENDES RIBEIRO RA, BRUNINI TM, ELLORY JC, MANN GE: Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc. Res. (2001) 49:697-712.
323. MACALLISTER RJ, WHITLEY GS, VALLANCE P et al.: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol. Dial. Transplant. (1996) 11:2449-2452.
324. BOGLE RG, MACALLISTER RJ, WHITLEY GS, VALLANCE P: Induction of NG-monomethyl-L-arginine uprake uptake: a mechanism for differential inhibition of NO synthases? Am. J. Physiol. (1995) 269:C750-C756.
325. VAZIRI ND, OVEISI F, DING Y: Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. (1998) 53:1748-1754.
326. NORIS M, REMUZZI G: Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc. Assoc. Am. Physicians (1999) 111:602-611.
327. MILLER HI, DASCALU A, RASSIN TA, WOLLMAN Y, CHERNICHOWSKY T, IAINA A: Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomised, parallel, double-blind clinical trial. Am. J. Nephrol. (2003) 23:91-95.
328. BENNETT-RICHARDS KJ, KATTENHORN M, DONALD AE et al.: Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int. (2002) 62:1372-1378.
329. FUJIHARA CK, MALHEIROS DM, DONATO JL, POLI A, DE NUCCI G, ZATZ R: Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Am. J. Physiol. (1998) 274:F573-F579.
330. WANG JL, CHENG HF, SHAPPELL S, HARRIS RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int. (2000) 57:2334-2342.
331. EPSTEIN M: Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J. Hypertens. (2002) 6:S17-S23.
332. CATTRAN DC, APPEL GB, HEBERT LA et al.: A randomised trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephritic Syndrome Study Group. Kidney Int. (1999) 56:2220-2226.
333. CATTRAN DC, APPEL GB, HEBERT LA et al.: Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomised trial. Kidney Int. (2001) 59:1484-1490.
334. ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 47:85-118.
335. ROMERO F, RODRIGUEZ B, PARRA G et al.: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. (1999) 55:945-955.
336. LAVILLE M, BADID C, FOUQUE D, DESMOULIERE A, VINCENT M: Mycophenolate mofetil: therapeutic potential in renal disease. Adv. Nephrol. Necker Hosp. (2000) 30:57-69.
337. MACPHEE IA, SPREAFICO S, BEWICK M et al.: Pharmacokinetics of mycophenolate mofetil in patients with end stage renal failure. Kidney Int. (2000) 57:1164-1168.
338. REMUZZI G, ZOJA C, GAGLIARDINI E, CORNA D, ABBATE M, BENIGNI A: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J. Am. Soc. Nephrol. (1999) 10:1542-1549.
339. FUJIHARA CK, NORONHA IL, ANTUNES GR et al.: Association of mycophenolate mofetil with an angiotensin II antagonist arrests ongoing renal injury in the remnant kidney. J. Am. Soc. Nephrol. (2000) 11:283-290.
340. HAMAR P, PETI-PETERDI J, RAZGA Z, KOVACS G, HEEMAN U, ROSIVALL L: Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney. J. Am. Soc. Nephrol. (1999) 10:S234-S238.
341. FRAMPTON JE, FAULDS D: Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs (1994) 47:652-676.
342. MORRIS TA: Heparin and low molecular weight heparin: background and pharmacology. Clin. Chest Med. (2003) 24:39-47.
343. LEONARD JV, MORRIS AA: Urea cycle disorders. Semin. Neonatol. (2002) 7:27-35.
344. BLEYER AJ: Phosphate binder usage in kidney failure patients. Expert Opin. Pharmacother. (2003) 4:941-947.
345. JOY MS, FINN WF: Randomised, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42:96-107.
346. D'HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. (2003) 85:S73-S78.
347. BROWN SA, BROWN CA, JACOBS G, STILES J, HENDI RS, WILSON S: Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am. J. Res. (2001) 62:375-383.
348. NO AUTHORS LISTED: Benazepril and the kidney: new indication. No better than other ACE inhibitors. Prescrire Int. (1998) 7:174-176.
349. BILLMAN GE: Ambrisentan (Myogen). Curr. Opin. Invest. Drugs. (2002) 3:1483-1486.
350. UHLMANN D, LUDWIG S, ESCHER E et al.: Protective effect of a selective endothelin A receptor antagonist (BSF 208075) on graft pancreatitis in pig pancreas transplantation. Transplant Proc. (2001) 33:3732-3734.
351. FISHER JW: Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (2003) 228:1-14.
352. ZHU H, JACKSON T, BUNN HF: Detecting and responding to hypoxia. Nephrol. Dial. Transplant. (2002) 17:3-7.
353. BUEMI M, CAVALLARO E, FLOCCARI F et al.: Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin. Sci. (2002) 103:275-282.
354. CERAMI A, BRINES M, GHEZZI P, CERAMI C, ITRI LM: Neuroprotective properties of epoetin alfa. Nephrol. Dial. Transplant. (2002) 17:8-12.
355. WESTENFELDER C: Unexpected renal actions of erythropoietin. Exp. Nephrol. (2002) 10:294-298.
356. THIEMERMANN C, ABDELRAHMAN M, PATEL N et al.: Erythropoietin reduces the renal injury caused by hemorrhagic shock or ischemia/reperfusion in the rat. Shock (2003) 19:72.
357. ELLIOT JM, VIRANKABUTRA T, JONES S et al.: Erythropoietin mimics the acute phase response in critical illness. Crit. Care (2003) 7:R35-R40.
358. CHRISTENSEN EI, BIRN H: Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev. (2002) 3:258-268.
359. VERROUST PJ, CHRISTENSEN EI: Megalin and cubilin - the story of two multipurpose receptors unfolds. Nephrol. Dial. Transplant. (2002) 17:1867-1871.
360. FYFE JC, RAMANUJAM KS, RAMASWAMY K et al.: Defective brush-border expression of intrinsic factor-cobalamin receptor in canine inherited intestinal cobalamin malabsorption. J. Biol. Chem. (1991) 266:4489-4494.
361. WILLNOW TE, HILPERT J, ARMSTRONG SA et al.: Defective forebrain development in mice lacking gp330/megalin. Proc. Natl. Acad. Sci. USA (1996) 93:8460-8464.
362. VERROUST PJ: Pathophysiology of cubilin: of rats, dogs and men. Nephrol. Dial. Transplant. (2002) 17:55-56.
363. SCHMIITZ C, HILPERT J, JACOBSEN C et al.: Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem. (2002) 277:618-622.
364. MOESTRUP SK, CUI S, VORUM H et al.: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. (1995) 96:1404-1413.
365. AL-AWQATI Q, OLIVER JA: Stem cells in the kidney. Kidney Int. (2002) 61:387-395.
366. POULSOM R, ALISON MR, COOK T et al.: Bone marrow stem cells contribute to healing of the kidney. J. Am. Soc. Nephrol. (2003) 14:S48-S54.
367. HERVE P: Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles to be cleared. Transplantation (2003) 75:55S-57S.
368. PFENDLER KC, KAWASE E: The potential of stem cells. Obstet. Gynecol. Surv. (2003) 58:197-208.
369. VERFAILLIE CM: Adult stem cells: assessing the case for pluripotency. Trends Cell. Biol. (2002) 12:502-508.
370. LIN F, CORDES K, LI L, HOOD L, COUSER WG, SHANKLAND SJ, IGARASHI P: Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J. Am. Soc. Nephrol. (2003) 14:1188-1199.
371. LAPING NJ, OLSON BA, ZHU Y: Identification of a novel nuclear guanosine triphosphate-binding protein differentially expressed in renal disease. J. Am. Soc. Nephrol. (2001) 12:883-890.
372. TOBACK FG, WALSH-REITZ MM, KARATHA S: Signals that release growth factors from renal epithelial cells. Am. J. Kidney Dis. (1991) 17:622-626.
373. ASTLES PC, BROWN TJ, HALLEY F et al.: Selective ET(A) antagonists. 5. Discovery and structure activity relationships of phenoxyphenylacetic acid derivatives. J. Med. Chem. (2000) 43:900-910.
374. WILLIAMS DL JR, MURPHY KL, NOLAN NA et al.: Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist. Life Sci. (1996) 58:1149-1157.